Thu. 25 Apr 2024, 6:40am ET
Benzinga
News, Guidance
The Company does not anticipate receipt of any additional milestone payments from collaborations in the remainder of 2024. The Company anticipates operating expenses will decrease in 2024 relative to 2023. With the availability of ZURZUVAE in the U.S. as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.